CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plusdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05084924
NCT05084924N/ACompleted
CompareCT.gov

Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonia

University of North Carolina, Chapel Hill·interventional·Posted Oct 20, 2021·Updated Jun 25, 2024

In Brief

A clinical study evaluating Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus for Major Depressive Disorder and Anhedonia. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can increase goal-directed behavior in participants with major depressive disorder and elevated symptoms of anhedonia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder, Anhedonia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 20, 2021
Enrollment StartNov 2, 2021
Primary CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.7 years ago

Interventions

Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plusdevice

Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.